Cargando…

Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma

The rapid development and remarkable success of checkpoint inhibitors have provided significant breakthroughs in cancer treatment, including hepatocellular carcinoma (HCC). However, only 15-20% of HCC patients can benefit from checkpoint inhibitors. Cancer stem cells (CSCs) are responsible for recur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Xiaomeng, Guo, Yixuan, Hu, Yan, Bao, Xuanwen, Zhu, Xudong, Fu, Qihan, Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Zheng, Yi, Zhao, Peng, Fang, Weijia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847682/ https://www.ncbi.nlm.nih.gov/pubmed/33537099 http://dx.doi.org/10.7150/thno.54648

Ejemplares similares

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
por: Bao, Xuanwen, et al.
Publicado: (2020)

Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
por: Zhang, Hangyu, et al.
Publicado: (2023)

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial
por: Fu, Qihan, et al.
Publicado: (2023)

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020)

An immunometabolism subtyping system identifies S100A9(+) macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis
por: Bao, Xuanwen, et al.
Publicado: (2023)

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
por: Zheng, Yi, et al.
Publicado: (2019)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy
por: Zheng, Hongyu, et al.
Publicado: (2023)

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)

Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma
por: Liu, Chuan, et al.
Publicado: (2023)

Targets of immunotherapy for hepatocellular carcinoma: An update
por: Rai, Vikrant, et al.
Publicado: (2022)

Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review
por: Yuan, Bao-Hong, et al.
Publicado: (2017)

Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy
por: Feng, Xiao-Chen, et al.
Publicado: (2023)

Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy
por: Zhang, Yan-Peng, et al.
Publicado: (2020)

Development, Validation and Comparison of Artificial Neural Network Models and Logistic Regression Models Predicting Survival of Unresectable Pancreatic Cancer
por: Tong, Zhou, et al.
Publicado: (2020)

Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine
por: Tong, Zhou, et al.
Publicado: (2020)

Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma
por: Tian, Bao-Wen, et al.
Publicado: (2022)

Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018)

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
por: Laface, Carmelo, et al.
Publicado: (2023)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Immunotherapies for hepatocellular carcinoma
por: Liu, Justin K. H., et al.
Publicado: (2021)

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
por: Zheng, Yi, et al.
Publicado: (2018)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
por: Chen, Pu, et al.
Publicado: (2021)

Advances in immunotherapy for hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2021)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Immunotherapy for recurrent hepatocellular carcinoma
por: Bhatt, Ahan, et al.
Publicado: (2023)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms
por: Tong, Zhou, et al.
Publicado: (2021)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy
por: Huang, Shao-Li, et al.
Publicado: (2021)

Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 predicts poor prognosis in hepatocellular carcinoma
por: Chen, Wanyuan, et al.
Publicado: (2018)

Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
por: Luo, Yi, et al.
Publicado: (2022)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy
por: Xue, Jian, et al.
Publicado: (2021)

An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma
por: Trifylli, Eleni-Myrto, et al.
Publicado: (2022)

Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma
por: Lin, Mingen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sbipjs6ggi44dqgu7n1hemsiso